Innovating ARDS Treatment AYX-201

Advancing cell therapy approaches for patients with severe respiratory failure

Picture2

Normal gas exchange across thin alveolar walls

Picture3

Fluid filled alveolar space preventing gas exchange

Acute Respiratory Distress Syndrome (ARDS)

TCNP encapsulated red cell therapy for pulmonary indications

  • ARDS is an acute, life-threatening condition with a ~40% mortality rate.
  • Excessive fluid buildup in the lungs/alveoli causes progressive lack of oxygenation.
  • There are no current FDA-approved drugs for prevention or treatment of ARDS or CARDS (Covid-associated).